The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
MSF, Unitaid and WHO authors discuss the need to improve access to liposomal amphotericin B (L-AmB) for the treatment of HIV-associated cryptococcal meningitis.
Thousands of deaths from a fungal infection of the brain called cryptococcal meningitis (CM) could potentially be averted every year in South Africa if an antifungal medicine called flucytosine is widely available.
It is unacceptable that people living with HIV are still dying because the tests, treatment and care for life-threatening infections are not available.
This week in Korea, the 16 countries of the Regional Comprehensive Economic Partnership (RCEP) agreement are meeting in Incheon for the 20th round of negotiations on this multilateral trade deal.
Manila is set to host the 18th round of the multilateral trade deal — the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population.
Today millions of people living with HIV in South-East Asia are receiving treatment and leading healthy lives thanks to affordable generic antiretroviral (ARVs) medicines.
Dr Maria Guevara says affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia